NCT01376752: CHIPOR

Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment

Active, enrolled Phase 3 Last updated 23 April 2025

What this trial tests

Phase 3 trial testing Maximal cytoreductive surgery in Ovarian Epithelial Cancer Recurrent in 415 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

26 April 2011

Primary endpoint
8 January 2023

14 May 2027

Quick facts

Lead sponsor	UNICANCER
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	415
Start date	26 April 2011
Primary completion	8 January 2023
Estimated completion	14 May 2027
Sites	33 locations across Belgium, France, Spain

Drugs / interventions tested

• Maximal cytoreductive surgery
• HIPEC — full drug profile →

Conditions studied

• Ovarian Epithelial Cancer Recurrent — all drugs for Ovarian Epithelial Cancer Recurrent →

Sponsor

UNICANCER — full company profile →

Who can join

18 and older, female only, with Ovarian Epithelial Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CHIPOR hypothesis is that the adjunction of platinum HIPEC in first relapsed epithelial ovarian cancer is able to improve the median Overall Survival (OS) by 12 months. In that hypothesis, with alpha risk of 5%, a power beta of 80%, during a 3 years period of inclusion and a 3 years follow-up, the number of patients to include is 404. Taking into account a 10% failure, an overall number of 444 patients is required.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Advances in ovarian cancer therapy.
   Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. · · 2018 · cited 417× · PMID 29249039 · DOI 10.1007/s00280-017-3501-8
2. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study.
   Glehen O, Passot G, Villeneuve L, Vaudoyer D, et al · · 2014 · cited 130× · PMID 24628950 · DOI 10.1186/1471-2407-14-183
3. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
   Haunschild CE, Tewari KS. · · 2020 · cited 72× · PMID 31746224 · DOI 10.2217/fon-2019-0042
4. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.
   Filis P, Mauri D, Markozannes G, Tolia M, et al · · 2022 · cited 70× · PMID 36116421 · DOI 10.1016/j.esmoop.2022.100586
5. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.
   Classe JM, Meeus P, Hudry D, Wernert R, et al · · 2024 · cited 41× · PMID 39549720 · DOI 10.1016/s1470-2045(24)00531-x
6. Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives.
   Spiliotis J, Halkia E, de Bree E. · · 2016 · cited 41× · PMID 27330364 · DOI 10.3747/co.23.2831
7. Hyperthermic Intraperitoneal Chemotherapy: A Critical Review.
   Ceelen W, Demuytere J, de Hingh I. · · 2021 · cited 34× · PMID 34206563 · DOI 10.3390/cancers13133114
8. The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review.
   Bhatt A, Glehen O. · · 2016 · cited 31× · PMID 27065709 · DOI 10.1007/s13193-016-0501-9